Healthcare Publications Gastrointestinal Drug Market

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine,
esophagus, liver, gallbladder and pancreas. The symptoms of GI diseases are heartburn,
indigestion, bloating, constipation and many more. According to a report by the World
Gastroenterology Organization, 35-40 % of world’s total population is suffering from acute
or chronic GI complication. Increasing patient having GI diseases and disorders, due to
change in dietary pattern are the major factor for increasing the global GI drug market. The
exact cause for inflammatory bowel disease and Irritable bowel syndrome are still unknown
due to which permanent cure for this disease is not available which may restrain the growth
of the market.
The Global Gastrointestinal Drug Market is expected to grow at CAGR of 4.8% during
forecasted period 2017- 2023. It is estimated to reach till USD $ 59.3 billion by end of
2024.
Segmentation
Global Gastrointestinal Drugs Market has been segmented on the basis of Drug Category
they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-
inflammatory drugs and other. By Route of Administration they are segmented into Oral,
Parenteral and rectal. By disease Type they are Gastroesophageal Reflux Disease,
Inflammatory Bowel Disease and Other. And by End User Hospital Pharmacies, Retail
Pharmacies and Other.
Acid Neutralizers which are further sub segmented into Antacids, H2 antagonists, Proton
pump inhibitors and Others,
Key Players for Global Gastrointestinal Drugs market
AbbVie Inc. (US), AstraZeneca (UK), Johnson & Johnson (US), Valeant (US), Abbott
Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US),
Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant
Pharmaceuticals (US), Sanofi (France), Janssen Biotech (US), GlaxoSmithKline Plc. (UK),
Boehringer Ingelheim GmbH (Germany).
Get Sample Copy at http://bit.ly/2J8jBKk .
Regional Analysis
North America, Europe, Asia Pacific and Middle East and Africa are the four major regional
segment of global GI drugs market.. North America account for the largest market share for
the global gastrointestinal drug market. Increasing geriatric population is the major driving
factor for the market of GI drugs in North America. Europe and Asia Pacific share nearly
similar amount of market. Introduction of new drugs and different technology has increased
the market in Asia Pacific and Europe. Asia Pacific is the most favourable region for the
development of GI drug market. Huge population and infrastructural improvement has
increases the scope for the development of this market in coming future.
Top Reasons to Buy the Reports:

Company profiling with detailed strategies, financials, and recent development
activities